149
Views
11
CrossRef citations to date
0
Altmetric
Review

Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence

, , , , , , , & , MD PhD show all
Pages 1571-1586 | Published online: 18 Nov 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yong Fang, Yi Hu, Peng Wu, Beibei Wang, Yuan Tian, Xi Xia, Qinghua Zhang, Tong Chen, Xuefeng Jiang, Quanfu Ma, Gang Xu, Shixuan Wang, Jianfeng Zhou, Ding Ma & Li Meng. (2011) Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341. Cancer Investigation 29:4, pages 247-252.
Read now

Articles from other publishers (10)

Anita K. Luu, Mia Cadieux, Mackenzie Wong, Rachel Macdonald, Robert Jones, Dongsic Choi, Michelle Oblak, Brigitte Brisson, Scott Sauer, James Chafitz, David Warshawsky, Geoffrey A. Wood & Alicia M. Viloria-Petit. (2022) Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle. International Journal of Molecular Sciences 23:6, pages 3256.
Crossref
Xin Jin, Yong Fang, Yi Hu, Jing Chen, Wei Liu, Gang Chen, Mei Gong, Peng Wu, Tao Zhu, Shixuan Wang, Jianfeng Zhou, Hui Wang, Ding Ma & Kezhen Li. (2017) Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines. Oncology Letters 13:6, pages 4619-4626.
Crossref
Kyle R. Cron, Kaya Zhu, Deepa S. Kushwaha, Grace Hsieh, Dmitry Merzon, Jonathan Rameseder, Clark C. Chen, Alan D. D’Andrea & David Kozono. (2013) Proteasome Inhibitors Block DNA Repair and Radiosensitize Non-Small Cell Lung Cancer. PLoS ONE 8:9, pages e73710.
Crossref
Myoung W. Lee, Dae S. Kim, Joo H. Lee, Bum S. Lee, Soo H. Lee, Hye L. Jung, Ki W. Sung, Heung T. Kim, Keon H. Yoo & Hong H. Koo. (2011) Roles of AKT1 and AKT2 in non-small cell lung cancer cell survival, growth, and migration. Cancer Science 102:10, pages 1822-1828.
Crossref
Mingxiang Liao, Ping Kang, Bernard P. Murray & Maria Almira Correia. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development 363 406 .
María Cortes-Sempere, Sharmila Chattopadhyay, Ana Rovira, Vanessa Rodriguez-Fanjul, Cristobal Belda-Iniesta, Marian Tapia, Paloma Cejas, Rosario Machado-Pinilla, Cristina Manguan-García, Isabel Sánchez-Pérez, Manuel Nistal, Carmen Moratilla, Javier de Castro-Carpeño, Manuel Gonzalez-Barón, Joan Albanell & Rosario Perona. (2009) MKP1 repression is required for the chemosensitizing effects of NF-κB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Letters 286:2, pages 206-216.
Crossref
Julia M. Huber, Andrea Tagwerker, Dorothea Heininger, Gert Mayer, Alexander R. Rosenkranz & Kathrin Eller. (2009) The proteasome inhibitor Bortezomib aggravates renal ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology 297:2, pages F451-F460.
Crossref
Jarmila Králová, Tomáš Bříza, Irena Moserová, Bohumil Dolenský, Petr Vašek, Pavla Poučková, Zdeněk Kejík, Robert Kaplánek, Pavel Martásek, Michal Dvořák & Vladimír Král. (2008) Glycol Porphyrin Derivatives as Potent Photodynamic Inducers of Apoptosis in Tumor Cells. Journal of Medicinal Chemistry 51:19, pages 5964-5973.
Crossref
Zhong Chen, Justin L. Ricker, Pramit S. Malhotra, Liesl Nottingham, Lorena Bagain, Tin Lap Lee, Ning T. Yeh & Carter Van Waes. (2008) Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-κB and activator protein-1 related mechanisms. Molecular Cancer Therapeutics 7:7, pages 1949-1960.
Crossref
Daniele Santini, Bruno Vincenzi & Giuseppe Tonini. (2008) Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma. Nature Clinical Practice Oncology 5:6, pages 304-305.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.